Article
Oncology
James L. Rubenstein
Summary: The Oncology Grand Rounds series aims to bridge the gap between research reports and clinical practice, helping readers better understand how to apply key research findings.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Leon D. Kaulen, Joachim M. Baehring
Summary: Primary CNS lymphoma (PCNSL) is a rare variant of non-Hodgkin lymphoma (NHL) with no consensus treatment. Selection of salvage therapy is based on patient's characteristics and response to previous treatments. High-dose methotrexate (HD-MTX) based regimens have shown high response rates, especially in relapsed patients. Myeloablative chemotherapy and autologous stem cell transplant are considered for patients in remission. Conventional chemotherapy or low-dose whole-brain radiation therapy may be used for consolidation in non-transplant candidates. Pemetrexed, temozolomide/rituximab, high-dose cytarabine, or whole brain radiation are alternative options for remission induction. Emerging therapies under investigation include bruton tyrosine kinase inhibition, immunomodulatory drugs, immune checkpoint inhibitors, and chimeric antigen receptor T cell therapy.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Oncology
Matthijs van der Meulen, Linda Dirven, Esther J. J. Habets, Katerina Bakunina, Marion Smits, Hakim C. Achterberg, Tatjana Seute, Gavin Cull, Harry Schouten, Josee M. Zijlstra, Dieta Brandsma, Roelien H. Enting, Max Beijert, Martin J. B. Taphoorn, Martin J. van den Bent, Samar Issa, Jeanette K. Doorduijn, Jacoline E. C. Bromberg
Summary: In patients with PCNSL, adding rituximab to standard treatment did not affect neurocognitive functioning up to 2 years post-treatment, and treatment with 30-Gy WBRT in patients aged 60 years or younger also did not impact neurocognition. Increased white matter abnormalities and brain atrophy showed weak associations with neurocognition.
Article
Oncology
Michelle Margold, Sabine Seidel, Thomas Kowalski, Swetlana Ladigan-Badura, Alexander Baraniskin, Roland Schroers, Anna Verena Frey, Ingo G. H. Schmidt-Wolf, Ulrich Herrlinger, Agnieszka Korfel, Uwe Schlegel
Summary: Bone marrow biopsy (BMB) has limited diagnostic and treatment impact in patients with presumed primary central nervous system lymphoma (PCNSL). The findings challenge the value of BMB as part of routine staging in presumed PCNSL.
Review
Oncology
Toby A. Eyre, Kerry J. Savage, Chan Y. Cheah, Tarec C. El-Galaly, Katharine L. Lewis, Pamela McKay, Matthew R. Wilson, Andrew M. Evens, Sabela Bobillo, Diego Villa, Matthew J. Maurer, Kate Cwynarski, Andres Ferreri
Summary: This Review provides a detailed discussion on the relapse of diffuse large B-cell lymphoma in the central nervous system, summarizing current prophylaxis strategies and associated clinical and biological features, while also offering insights into possible future developments.
Review
Oncology
Lauren R. Schaff, Christian Grommes
Summary: Primary central nervous system lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that is highly responsive to first-line chemo and radiation treatments but has high rates of relapse, necessitating the development of novel therapeutic strategies. Recent advancements in understanding the pathophysiology of this disease have identified new potential treatment targets, leading to the development of promising novel agents. Ongoing clinical trials are investigating targeted strategies and novel agents for the treatment of PCNSL.
Editorial Material
Hematology
Mark Roschewski, James D. Phelan
Summary: In this study, Gandhi et al analyzed 91 cases of primary diffuse large B-cell lymphoma of the central nervous system and compared the biological features of tumors associated with Epstein-Barr virus to those that are not associated using digital gene expression signatures and customized sequencing panels.
Article
Oncology
Andrew B. DeAtkine, Moaaz Abdelrashid, Zach Tucker, Amitkumar Mehta, James M. Markert, Jinsuh Kim, John B. Fiveash, Robert A. Oster, Mina Lobbous, L. Burt Nabors
Summary: The study found that there was no significant difference in survival outcomes between PCNSL patients receiving MTX plus rituximab and those receiving MTX alone. Lower doses of MTX were associated with worse survival outcomes. Age may have some impact on survival results.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Hematology
Paul Lesueur, Gandhi Damaj, Khe Hoang-Xuan, Virginie Roland, Anna Schmitt, Olivier Chinot, Michel Fabbro, Philippe Agape, Cecile Molucon-Chabrot, Safia Chebrek, Agusti Alentorn, Loic Feuvret, Daniel Delgadillo, Dinu Stefan, Sylvain Choquet, Lucia Nichelli, Karima Mokhtari, Bertrand Mathon, Sylvain Dureau, Carole Soussain, Caroline Houillier
Summary: This study retrospectively examined the feasibility of using reduced-dose whole-brain radiotherapy (rdWBRT) as consolidation treatment for primary central nervous system lymphoma (PCNSL) in patients aged <60 years. The results showed no significant difference in progression-free survival and overall survival between rdWBRT and standard-dose WBRT (sdWBRT), and most patients exhibited maintenance or improvements in their neuropsychological conditions.
Article
Oncology
Pier Luigi Zinzani, Thomas Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan H. Fowler, Gilles Salles, Bruce Feinberg, Nuwan C. Kurukulasuriya, Sascha Tillmanns, Stephan Parche, Debarshi Dey, Gunter Fingerle-Rowson, Sumeet Ambarkhane, Mark Winderlich, Grzegorz S. Nowakowski
Summary: The study demonstrated the additional treatment effect achieved by combining tafasitamab with lenalidomide in patients with R/R DLBCL, showing higher overall response rate, complete response rate, and improved survival endpoints compared to lenalidomide monotherapy.
CLINICAL CANCER RESEARCH
(2021)
Article
Clinical Neurology
Philipp Karschnia, Sylvia C. Kurz, Priscilla K. Brastianos, Sebastian F. Winter, Amanda Gordon, Sooae Jones, Michelle Pisapia, Naema Nayyar, Joerg-Christian Tonn, Tracy T. Batchelor, Scott R. Plotkin, Jorg Dietrich
Summary: This study investigates the association between MTHFR polymorphisms and the risk of leukoencephalopathy, and finds that the 1298A -> C genotype is associated with an increased frequency and severity of leukoencephalopathy.
Review
Oncology
Florian Scheichel, Daniel Pinggera, Branko Popadic, Camillo Sherif, Franz Marhold, Christian Franz Freyschlag
Summary: Primary central nervous system lymphomas (PCNSL) are rare tumors with longer diagnostic delay. The gold standard for diagnosis is histopathological analysis and comprehensive diagnostic workup. Current standards of imaging and surgical workup play a key role in reducing the diagnostic delay.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Ayush Agarwal, Jyoti Sharma, M. V. Padma Srivastava, M. C. Sharma, Rohit Bhatia, Deepa Dash, Vinay Goyal, Achal K. Srivastava, Manjari Tripathi, Vaishali Suri, Mamta B. Singh, Sushant Agarwal, Chitra Sarkar, Leve Joseph, Manmohan Singh, Ashish Suri, Rajesh K. Singh, Deepti Vibha, Awadh K. Pandit, Roopa Rajan, Anu Gupta, A. Elavarasi, Divya M. Radhakrishnan, Animesh Das, Shailesh Gaikwad, Vivek Tandon, Ramesh Doddamani, Ashish Upadhyay, Ajay Garg, Venugopalan Y. Vishnu
Summary: Primary CNS Vasculitis (PCNSV) is a rare inflammatory disorder that affects the blood vessels of the central nervous system. This study aimed to identify factors associated with the 2-year outcome in patients with PCNSV. The study included 82 biopsy and/or angiographically proven PCNSV cases, and observed clinical, imaging, and histopathologic findings, as well as treatment and functional outcomes. The study found that myelitis and longer duration of illness before diagnosis were associated with poorer outcomes, and hemorrhages on SWI sequence of MRI might be a sensitive imaging marker.
SCIENTIFIC REPORTS
(2022)
Letter
Medicine, General & Internal
Leonid L. Yavorkovsky
Summary: The median survival of mantle-cell lymphoma is a puzzling issue. Despite the historically modest benefits of rituximab therapy, the introduction of rituximab has substantially improved the survival probability among patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Kexin Feng, Shuangtao Zhao, Qingyao Shang, Guangdong Qiao, Jiaxiang Liu, Chenxuan Yang, Ya Wei, Yalun Li, Fei Ren, Lixue Xuan, Xiang Wang, Xin Wang
Summary: The study confirmed the prognostic value of IPI in patients with PBL, but its predictive value was relatively low with the addition of rituximab. R-IPI and NCCN-IPI could accurately assess the high and low-risk groups of PBL patients but were insufficient for evaluating the intermediate risk group.
CANCER CELL INTERNATIONAL
(2022)
